
|Articles|September 4, 2014
Recurrence and Tailoring Radiotherapy Following Neoadjuvant Chemotherapy
Author(s)Eleftherios Mamounas, MD, MPH
Eleftherios Mamounas, MD, MPH, discusses locoregional recurrence and tailoring radiotherapy following neoadjuvant chemotherapy.
Advertisement
Clinical Pearls
Eleftherios Mamounas, MD, MPH, medical director, Comprehensive Breast Program, University of Florida Health Cancer Center, discusses locoregional recurrence and tailoring radiotherapy following neoadjuvant chemotherapy.
- Researchers are trying to understand whether the response and tumor subtype of patients treated with neoadjuvant chemotherapy can help to tailor the use of radiotherapy afterwards.
- Though the data from this analysis do not provide a definitive answer, they help researchers understand that these patients had low rates of recurrence and tailoring radiotherapy is possible. Trials are in progress to test this concept.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
5



























